Pfizer Inc. (NYSE:PFE) Shares Bought by RFG Advisory LLC

RFG Advisory LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 36.6% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 35,038 shares of the biopharmaceutical company’s stock after purchasing an additional 9,380 shares during the quarter. RFG Advisory LLC’s holdings in Pfizer were worth $1,519,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the business. Evolution Wealth Advisors LLC purchased a new stake in shares of Pfizer during the 2nd quarter worth $34,000. IMA Wealth Inc. boosted its position in shares of Pfizer by 144.5% in the 2nd quarter. IMA Wealth Inc. now owns 807 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 477 shares in the last quarter. Winch Advisory Services LLC boosted its position in shares of Pfizer by 69.6% in the 4th quarter. Winch Advisory Services LLC now owns 819 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 336 shares in the last quarter. Financial Gravity Wealth Inc. boosted its position in shares of Pfizer by 33.2% in the 2nd quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 257 shares in the last quarter. Finally, Karp Capital Management Corp purchased a new stake in shares of Pfizer in the 4th quarter worth about $53,000. 71.68% of the stock is currently owned by institutional investors.

In other news, major shareholder Pfizer Inc bought 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 17th. The stock was acquired at an average price of $18.00 per share, with a total value of $900,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Scott Gottlieb bought 3,000 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The shares were purchased at an average cost of $34.72 per share, with a total value of $104,160.00. Following the purchase, the director now directly owns 3,000 shares of the company’s stock, valued at $104,160. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by company insiders.

A number of research firms have recently commented on PFE. Goldman Sachs Group reaffirmed a “buy” rating and set a $49.00 price objective on shares of Pfizer in a research note on Monday, June 17th. JPMorgan Chase & Co. upped their price objective on shares of Pfizer from $37.00 to $46.00 and gave the company a “neutral” rating in a research note on Thursday, September 19th. They noted that the move was a valuation call. Bank of America downgraded shares of Pfizer from a “buy” rating to a “neutral” rating in a research note on Tuesday, July 30th. DZ Bank raised shares of Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price objective for the company in a research note on Wednesday, August 28th. Finally, Morgan Stanley dropped their price objective on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a research note on Tuesday, August 27th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. Pfizer currently has a consensus rating of “Hold” and a consensus target price of $45.41.

Shares of PFE traded down $0.41 during trading hours on Tuesday, reaching $35.52. 10,408,277 shares of the company’s stock traded hands, compared to its average volume of 20,282,714. The firm has a market capitalization of $200.33 billion, a price-to-earnings ratio of 11.84, a P/E/G ratio of 2.88 and a beta of 0.66. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.47 and a quick ratio of 1.21. Pfizer Inc. has a twelve month low of $33.97 and a twelve month high of $46.47. The business’s fifty day simple moving average is $35.80 and its two-hundred day simple moving average is $40.28.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.75 by $0.05. The company had revenue of $13.26 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 28.10% and a net margin of 23.58%. The company’s quarterly revenue was down 1.5% compared to the same quarter last year. During the same period last year, the company earned $0.77 earnings per share. On average, equities research analysts expect that Pfizer Inc. will post 2.81 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a dividend of $0.36 per share. This represents a $1.44 dividend on an annualized basis and a dividend yield of 4.05%. The ex-dividend date is Thursday, November 7th. Pfizer’s dividend payout ratio (DPR) is 48.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: What is a Futures Contract?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.